PRPH - Kewajiban jangka dawa marang modal ProPhase Labs Corp

Logo korporat perusahaan ProPhase Labs Corp (PRPH)

ProPhase Labs, Inc. (PRPH) relies on a network of diagnostic centers and the sale of dietary supplements. The long-term financial leverage ratio visualizes the current balance of debt and equity, where 0.14 expresses the latest level of the metric. The holding company utilizes resources from PCR tests to develop genomics and oncology, although a decline in demand for testing has temporarily increased the company's unit costs.

ProPhase Labs (PRPH): Utang jangka dawa marang modal saka 04.07.2022 nganti 10.01.2026
Barang utama ProPhase Labs, Inc.

When constructing a long-term portfolio, fundamental screening requires strict control over debt load. This ratio compares liabilities with maturities exceeding one year to total equity, determining the degree of financial leverage. For ProPhase Labs, Inc. (PRPH), which is developing diagnostics and nutraceuticals, moderate leverage is critical when scaling pharmacy sales. By analyzing the long-term debt-to-equity chart, an investor assesses the stability of the financing structure, which allows for the determination of the risk associated with the business's dependence on external borrowings.

Karo sapa ProPhase Labs, Inc. saingan

Rasio utang jangka dawa marang ekuitas Agilent Technologies, Inc.|Quest - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Illumina Platform (ILMN)|EXAS - Utang jangka dawa marang modal|Rasio utang jangka dawa marang modal revvity.com RVTY|Bio-Rad - Utang jangka dawa marang modal|NNNN: Utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Sterigenics|QuidelOrtho Inc. (QDEL) - Rasio utang jangka dawa marang modal|OPK (OPKO Health, Inc.) - Utang jangka dawa marang modal|Utang jangka dawa marang modal CDNA|Utang jangka dawa marang ekuitas Maravai LifeSciences Holdings, Inc. (MRVI)|Utang jangka dawa marang ekuitas Fulgent Genetics Inc FLGT|LAB: Rasio utang jangka dawa marang ekuitas|Cytek Corp - Kewajiban jangka dawa marang modal|Utang jangka dawa marang ekuitas OSUR (OraSure Technologies)|XGN - Rasio tanggungan utang jangka dawa marang modal|MDxHealth - Utang jangka dawa marang modal|LUCD (Lucid Diagnostics, Inc.) - Rasio tanggungan utang jangka dawa marang modal|PRE: Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal IMDX|TRIB - Utang jangka dawa marang ekuitas|Kewajiban jangka dawa marang ekuitas AIMD (ainos.com)|Utang jangka dawa marang ekuitas Co-Diagnostics|Heart Test Laboratories, Inc. - Koefisien utang jangka dawa marang modal|BMRA (Biomerica, Inc) - Utang jangka dawa marang ekuitas|CDIO: Kewajiban jangka dawa marang modal|Utang jangka dawa marang ekuitas Virax Biolabs Group (VRAX)|bluejaydx.com (BJDX) - Kewajiban jangka dawa marang ekuitas|AWH - Utang jangka dawa marang modal|Koefisien utang jangka dawa marang modal Accelerate Diagnostics Inc.|Utang jangka dawa marang modal CNTG|Utang jangka dawa marang modal ENZ (enzo.com)|Utang jangka dawa marang ekuitas FRES|Rasio tanggungan utang jangka dawa marang modal Genetic Technologies Ltd GENE|ME (23andMe) - Utang jangka dawa marang modal|Psychemedics Corp. (PMD) - Kewajiban jangka dawa marang modal